CARMEN J. CONICELLI JOINS BOARD OF DIRECTORS OF CDEX INC. REPLACING DR. BD LIAW
                        WHO RESIGNS FOR HEALTH REASONS.

TUCSON, AZ. - October 9, 2007 - CDEX Inc. (OTCBB: CEXI) announces that Carmen J.
Conicelli replaces Dr. BD Liaw, Chairman of the Board, on the CDEX Board of
Directors. Dr. Liaw, who resigned from the Board for health reasons, will
continue to support CDEX particularly in relation to establishing international
markets for CDEX products. Malcolm H. Philips, President and CEO, will assume
the additional responsibilities of Chairman.

"It is with deep personal regret that the Company accepts Dr. Liaw's
resignation," said Mr. Philips. "Dr. Liaw has had a long and distinguished
careen of service to this country in senior executive positions with the U.S.
Nuclear Regulatory Commission, to Taiwan Power Company as an Executive Director
and senior consultant, and to CDEX as a founding Director and later as Chairman
of the Board. I know that he will continue to provide strong and effective
support for CDEX as we move into international markets."

Mr. Conicelli is the CFO of Edmund Optics, Inc. and has had a distinguished
career in finance and management. . "CDEX is pleased to have Mr. Conicelli join
us as a Board member," said Mr. Philips. "He brings more than 30 years of
experience in finance and accounting to the Board with a strong background in
the international finance and business. Mr. Carmen will be invaluable to CDEX as
we broaden our domestic markets and enter the international medical and security
markets."

About CDEX, Inc.

CDEX Inc. is a technology development company with a current focus on developing
and marketing products using chemical detection and validation technologies. At
present, CDEX is applying its resources in two distinct areas: (I)
identification of substances of concern (e.g., explosives and illegal drugs for
homeland security); and (II) validation of substances for anti-counterfeiting,
brand protection and quality assurance (e.g., validation of prescription
medication and detection of counterfeit or sub-par products for brand
protection). ValiMed(TM) is a CDEX solution for the healthcare market. Corporate
headquarters and research and development facilities for CDEX are located in
Tucson, Arizona. For more information, visit www.cdex-inc.com and
www.valimed.com or contact Malcolm Philips (mphilips@cdex-inc.com) or Stuart
Poteet (spoteet@cdex-inc.com) at 520.745.5172 X 210 or 202.

Any statements made in this press release which contain information that is not
historical are essentially forward-looking, as that term is defined in the
federal securities laws. Many forward-looking statements can be identified by
the use of words such as "expects," "plans," "may," "anticipates," "believes,"
"should," "intends," "estimates," and other words of similar meaning. These
statements are subject to risks and uncertainties that cannot be predicted or
quantified and, consequently, actual results may differ materially from those
expressed or implied by such forward-looking statements. Such risks and
uncertainties include, without limitation, the ability of the Company to raise
capital to finance the development of its products, the effectiveness,
profitability and marketability of those products, the ability of the Company to
protect its proprietary information, the establishment of an efficient corporate
operating structure as the Company grows and, other risks detailed from
time-to-time in filings with the Securities and Exchange Commission. There is no
obligation to publicly update any forward-looking statements.